These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 6098495)

  • 1. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic characterization of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Spitz M; Schild GC
    Rev Infect Dis; 1984; 6 Suppl 2():S510-3. PubMed ID: 6204368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
    J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
    Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
    Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenicity and immunogenicity of poliovirus capsid proteins.
    van Wezel AL; van der Marel P; Hazendonk TG; Boer-Bak V; Henneke MA
    Dev Biol Stand; 1983; 55():209-15. PubMed ID: 6203795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides.
    Thorpe R; Minor PD; Mackay A; Schild GC; Spitz M
    J Gen Virol; 1982 Dec; 63(2):487-92. PubMed ID: 6185628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
    Minor PD; Schild GC; Evans D; Ferguson M; Almond J
    Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
    Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
    Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of neutralizing antibodies by type 1 poliovirus VP1 capsid polypeptide.
    Crainic R; Blondel B; Horaud F
    Dev Biol Stand; 1983; 55():185-9. PubMed ID: 6329856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies reveal in blocking reactions the antigenicity and antibody response of poliovirus.
    Uhlig H; Rutter G; Dernick R
    Dev Biol Stand; 1984; 57():187-91. PubMed ID: 6084610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
    Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
    J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic sites on type 2 poliovirus.
    Patel V; Ferguson M; Minor PD
    Virology; 1993 Jan; 192(1):361-4. PubMed ID: 7685967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains.
    Ferguson M; Magrath DI; Minor PD; Schild GC
    Bull World Health Organ; 1986; 64(2):239-46. PubMed ID: 3017595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybridoma cell lines secreting monoclonal antibodies to foot-and-mouth disease virus type Asia-1.
    Butchaiah G; Rao BU
    Acta Virol; 1989 Mar; 33(2):121-30. PubMed ID: 2569807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antigen differences of genetic variants Abent+ and Abent- poliovirus vaccine strain of III type].
    Shyrobokov VP; Kostenko IH; Nikolaienko IV
    Mikrobiol Z; 2003; 65(4):29-36. PubMed ID: 14618784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
    Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
    Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization epitope patterns of poliovirus strains isolated from paralytic cases.
    Crainic R; Blondel B; Aubert-Combiescu A; Beytout D; Couillin P; Candrea A; Boué A; Horaud F
    Dev Biol Stand; 1984; 57():165-70. PubMed ID: 6084607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.